Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 7/20 | 0.44 |
| ▸ | RXRA | P19793 | 6/20 | 0.44 |
| ▸ | RXRG | P48443 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19056879 | 0.84 | MAPT (0.55) | ACHEGABRA1GABRB2RXRBRXRA | |
| SCHEMBL27857311 | 0.83 | ACHE (0.46) | ACHEGABRA1GABRB2RXRBRXRA | |
| SCHEMBL28321265 | 0.81 | SMN1; SMN2 (0.44) | ACHEMEN1KMT2AMAPTNPC1 | |
| SCHEMBL6971428 | 0.81 | CA12 (0.49) | MEN1KMT2AMAPTNPC1MAPK1 | |
| SCHEMBL1927936 | 0.81 | GSK3B (0.46) | ACHEGABRA1GABRB2RXRBRXRA | |
| SCHEMBL6581884 | 0.80 | ACHE (0.72) | ACHERXRBRXRAMEN1KMT2A | |
| SCHEMBL8153195 | 0.79 | HSD17B3 (0.47) | ACHEGABRA1GABRB2RXRBRXRA | |
| SCHEMBL12801046 | 0.79 | RXRA (0.46) | ACHEGABRA1GABRB2RXRBRXRA | |
| SCHEMBL5874076 | 0.78 | RAB9A (0.63) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL19281439 | 0.78 | CES2 (0.61) | RXRBRXRARXRGHDAC3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1625112-B1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20060128662-A1 | Novel compounds for treatment of obesity | NOVO NORDISK A/S (DK) | 2006-06-15 | — | — | US | disclosed |
| EP-1625112-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004101505-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-11-25 | — | — | WO | disclosed |
| US-6083977-A | HAVING ACTIVITY FOR RETINOIC ACID RECEPTORS AND RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0800503-B1 | NOVEL TRIENOIC RETINOID COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2000-05-10 | — | — | EP | disclosed |
| US-5721103-A | SKIN DISORDERS; VISION DEFECTS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1998-02-24 | — | — | US | disclosed |
| WO-1996020913-A1 | NOVEL TRIENOIC RETINOID COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128662-A1 | Novel compounds for treatment of obesity | GPR119, FABP4, HSD17B4 | ACHE 4676/4885GABRA1 2118/4885GABRB2 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.